Drug Trial News

RSS

Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Key data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical trial programme, HCVerso, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities.

6 Apr 2012

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system completed a pharmacokinetic (PK) study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome.

6 Apr 2012

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Research from The Cancer Institute of New Jersey (CINJ) shows that a series of vaccine injections given directly into a pancreatic cancer tumor is shown to be associated with stable disease in patients who are not candidates for surgery.

5 Apr 2012

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine.

5 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

Soy may effectively reduce menopausal hot flashes

In the most comprehensive study to date to examine the effects of soy on menopause, researchers have found that two daily servings of soy can reduce the frequency and severity of hot flashes by up to 26 percent, compared to a placebo.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Soy isoflavones more effective in alleviating hot flashes

Archer Daniels Midland Company is pleased to share the results of a new meta-analysis on the effects of soy isoflavones in the alleviation of menopausal hot flashes.

5 Apr 2012

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University.

5 Apr 2012

Oral fluoroquinolones increase risk of retinal detachment

In an analysis of a cohort that included nearly one million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.

4 Apr 2012

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

Drug Trial News

Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Sucampo announces positive results from lubiprostone phase 3 trial on OBD

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Soy may effectively reduce menopausal hot flashes

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

Soy isoflavones more effective in alleviating hot flashes

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Oral fluoroquinolones increase risk of retinal detachment

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

MedImmune's quadrivalent flu vaccine may protect children

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

Combination of gemcitabine and TH-302 improves survival in advanced pancreatic cancer

Topline results from GSK's seven of eight albiglutide Phase 3 studies on type 2 diabetes

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News